PD-L1 Antikörper
Kurzübersicht für PD-L1 Antikörper (ABIN5526896)
Target
Alle PD-L1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Verwendungszweck
- Anti-Hu CD274 Purified
-
Spezifität
- The mouse monoclonal antibody 29E.2A3 recognizes an extracellular epitope of CD274 / PD-L1 (also known as B7-H1), a 40 kDa type I transmembrane protein expressed by dendritic cells, activated T cells, activated monocytes, and in various tissues, above all in heart and skeletal muscle, placenta and lung, and in many cancer cells, including T cell lymphomas, melanomas, and glioblastomas.
-
Kreuzreaktivität (Details)
- Human, Non-Human Primates
-
Aufreinigung
- Purified by protein-A affinity chromatography.
-
Reinheit
- > 95 % (by SDS-PAGE)
-
Immunogen
- Full length human CD274
-
Isotyp
- IgG2b kappa
-
-
-
-
Applikationshinweise
-
Immunohistochemistry (frozen sections): Acetone fixation.
Flow cytometry: Recommended dilution: 1-4 μg/mL -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1 mg/mL
-
Buffer
- Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- Store at 2-8°C. Do not freeze.
-
-
- PD-L1 (CD274 (PD-L1))
-
Andere Bezeichnung
- CD274
-
Hintergrund
- CD274 Molecule,CD274 / PD-L1 (programmed death ligand-1), also known as B7-H1, is a member of the B7 family of regulatory proteins. It can act as both costimulatory and coinhibitory molecule for T cells. Interaction with its receptor CD279 (PD1) appears to be important in the maintenance of peripheral tolerance and in prevention of tumor rejection. Even pathogens (e.g. Schistosoma) may exploit CD274 to evade an immune response. Besides CD279, existence of other receptor(s) for CD274 is likely.,B7H1, PDL1, PDCD1L1, PDCD1LG1, PDCD1 ligand 1, B7-H1
-
Gen-ID
- 29126
-
UniProt
- Q9NZQ7
-
Pathways
- Cancer Immune Checkpoints
Target
-